AKAP9

Summary

AKAP9 (A-kinase anchoring protein 9, HGNC:379) is a protein-coding gene on chromosome 7q21.2, encoding A-kinase anchor protein 9 (Q99996). Scaffolding protein that assembles several protein kinases and phosphatases on the centrosome and Golgi apparatus.

The A-kinase anchor proteins (AKAPs) are a group of structurally diverse proteins which have the common function of binding to the regulatory subunit of protein kinase A (PKA) and confining the holoenzyme to discrete locations within the cell. This gene encodes a member of the AKAP family. Alternate splicing of this gene results in at least two isoforms that localize to the centrosome and the Golgi apparatus, and interact with numerous signaling proteins from multiple signal transduction pathways. These signaling proteins include type II protein kinase A, serine/threonine kinase protein kinase N, protein phosphatase 1, protein phosphatase 2a, protein kinase C-epsilon and phosphodiesterase 4D3.

Source: NCBI Gene 10142 — RefSeq curated summary.

At a glance

• Gene–disease (curated): male infertility with azoospermia or oligozoospermia due to single gene mutation (Moderate, GenCC) — +2 more curated relationships
• GWAS associations: 8
• Clinical variants (ClinVar): 3,716 total — 1 pathogenic, 4 likely-pathogenic
• Phenotypes (HPO): 25
• Cancer driver (intOGen): activating (oncogene-like) across 10 cancer types
• MANE Select transcript: NM_005751

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:379
Approved symbol	AKAP9
Name	A-kinase anchoring protein 9
Location	7q21.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0803, AKAP350, AKAP450, CG-NAP, YOTIAO, HYPERION, PRKA9, MU-RMS-40.16A, PPP1R45, LQT11
Ensembl gene	ENSG00000127914
Ensembl biotype	protein_coding
OMIM	604001
Entrez	10142

Gene structure

Transcript identifiers

Ensembl transcripts: 35 — 18 protein_coding, 10 retained_intron, 6 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000356239, ENST00000359028, ENST00000394534, ENST00000394564, ENST00000435423, ENST00000463118, ENST00000484815, ENST00000486313, ENST00000487258, ENST00000487692, ENST00000491695, ENST00000493453, ENST00000674381, ENST00000679448, ENST00000679457, ENST00000679474, ENST00000679521, ENST00000679554, ENST00000679722, ENST00000679821, ENST00000680047, ENST00000680072, ENST00000680074, ENST00000680181, ENST00000680365, ENST00000680513, ENST00000680534, ENST00000680766, ENST00000680952, ENST00000681216, ENST00000681412, ENST00000681722, ENST00000925975, ENST00000925976, ENST00000925977

RefSeq mRNA: 3 — MANE Select: NM_005751 NM_001379277, NM_005751, NM_147185

CCDS: CCDS5622, CCDS94141, CCDS94142

Canonical transcript exons

ENST00000356239 — 50 exons

Exon	Start	End
ENSE00000434664	92089385	92089529
ENSE00000434665	92093097	92093316
ENSE00000918935	92086228	92086416
ENSE00000918940	92079079	92080152
ENSE00000918949	92052726	92052958
ENSE00000918950	92045008	92045213
ENSE00000918951	92042668	92042771
ENSE00000918952	92042046	92042186
ENSE00001031186	92040674	92040898
ENSE00001396791	91940862	91941147
ENSE00001518744	92110122	92110673
ENSE00001610507	92085495	92085686
ENSE00001615779	92084640	92084703
ENSE00001727716	92084819	92084940
ENSE00001747828	92082522	92082662
ENSE00001765764	92083170	92083655
ENSE00002432222	92076855	92077007
ENSE00002440884	92070030	92070206
ENSE00002469294	92077696	92077875
ENSE00002504189	92070905	92071009
ENSE00002523196	92066427	92066546
ENSE00002707317	92065231	92065463
ENSE00003462858	91995603	91995800
ENSE00003464483	92097586	92097794
ENSE00003476965	92102594	92102826
ENSE00003484877	92000848	92003235
ENSE00003490760	92095023	92095173
ENSE00003515378	91994621	91994776
ENSE00003518175	92029895	92029991
ENSE00003522563	92096689	92097357
ENSE00003529688	92017017	92017102
ENSE00003542008	92016129	92016267
ENSE00003550230	92031512	92031604
ENSE00003561325	92107293	92107422
ENSE00003563282	92022238	92022352
ENSE00003563337	92061260	92061422
ENSE00003565503	92014249	92014328
ENSE00003575362	91992885	91993055
ENSE00003575995	92038419	92038772
ENSE00003584199	91992158	91992211
ENSE00003596992	92100856	92101056
ENSE00003608380	92098109	92098214
ENSE00003610052	92012429	92012642
ENSE00003617904	91980289	91980333
ENSE00003631847	92022814	92023009
ENSE00003637094	92062274	92062486
ENSE00003662552	92099687	92099869
ENSE00003666256	92108494	92108633
ENSE00003671590	92105678	92105763
ENSE00003682193	91973711	91973968

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 98.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.2660 / max 818.1560, expressed in 1802 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79498	24.8928	1792
79499	3.2037	1044
79501	0.9770	395
79514	0.6955	259
79515	0.5915	231
79508	0.5708	206
79497	0.4508	225
79512	0.3616	143
79500	0.3135	133
79511	0.1275	82

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	98.85	gold quality
bronchial epithelial cell	CL:0002328	98.12	gold quality
cortical plate	UBERON:0005343	97.60	gold quality
epithelium of bronchus	UBERON:0002031	97.43	gold quality
sural nerve	UBERON:0015488	97.33	gold quality
bronchus	UBERON:0002185	97.26	gold quality
adrenal tissue	UBERON:0018303	97.17	gold quality
calcaneal tendon	UBERON:0003701	97.00	gold quality
jejunum	UBERON:0002115	96.68	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	96.41	gold quality
colonic epithelium	UBERON:0000397	96.31	gold quality
mucosa of stomach	UBERON:0001199	96.16	gold quality
right uterine tube	UBERON:0001302	96.15	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	96.11	gold quality
mucosa of paranasal sinus	UBERON:0005030	96.10	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	96.03	gold quality
colonic mucosa	UBERON:0000317	96.00	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	95.92	gold quality
mucosa of sigmoid colon	UBERON:0004993	95.91	gold quality
biceps brachii	UBERON:0001507	95.80	gold quality
tibia	UBERON:0000979	95.53	gold quality
duodenum	UBERON:0002114	95.40	gold quality
endometrium epithelium	UBERON:0004811	95.35	gold quality
body of pancreas	UBERON:0001150	95.33	gold quality
vastus lateralis	UBERON:0001379	95.25	gold quality
diaphragm	UBERON:0001103	95.23	gold quality
gluteal muscle	UBERON:0002000	95.21	gold quality
renal medulla	UBERON:0000362	95.15	gold quality
rectum	UBERON:0001052	95.06	gold quality
ganglionic eminence	UBERON:0004023	94.98	gold quality

Single-cell (SCXA)

Detected in 12 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-GEOD-137537	yes	3443.56
E-MTAB-11121	yes	2912.35
E-HCAD-1	yes	26.33
E-MTAB-5061	yes	15.62
E-GEOD-130148	yes	11.03
E-HCAD-9	yes	9.44
E-GEOD-98556	no	4806.33
E-CURD-135	no	1728.66
E-MTAB-7316	no	31.35
E-HCAD-31	no	5.24
E-GEOD-83139	no	3.82
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

52 targeting AKAP9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-133A-3P	99.27	71.53	1270

Literature-anchored findings (GeneRIF, showing 39)

• included in a macromolecular complex with PKA and PP1 which is required for the regulation of hKCNQ1 by PKA-dependent phosphorylation (PMID:11799244)
• CG-NAP and kendrin provide sites for microtubule nucleation in the mammalian centrosome by anchoring gamma-TuRC (PMID:12221128)
• findings support a model in which sub-cellular localization at the centrosome is mediated, at least in part, through the action of CG-NAP/AKAP450 (PMID:12270714)
• InsP(3)R1-PKA association is mediated by AKAP9; InsP(3)R1-AKAP9 binding promotes association of neuronal InsP(3)R1 with the NR1 NMDA receptor; and neuronal InsP(3)R1 associate with PP1 directly via carboxy-terminus and indirectly via AKAP9 (PMID:14982933)
• AKAP9-BRAF fusion was preferentially found in radiation-induced papillary carcinomas developing after a short latency, whereas BRAF point mutations were absent in this group (PMID:15630448)
• These results suggest that CG-NAP/D causes centrosome amplification by anchoring excess amount of cyclin E-cdk2 to centrosomes and, possibly, CG-NAP participates in centrosome duplication by recruiting cyclin E-cdk2 to centrosomes in normal cell cycle. (PMID:15670215)
• expression of the intact CG-NAP/AKAP450 and its recruitment to the LFA-1-associated multimolecular complex is critically important for polarization and migration of T cells induced by this integrin. (PMID:16339516)
• AKAP350 has a role in the remodeling of the microtubule cytoskeleton. (PMID:16356588)
• CG-NAP is recruited to the minus ends of microtubules by interacting with cytoplasmic dynein, thereby localizes to the Golgi apparatus in a microtubule-dependent manner and possibly involved in the formation of the Golgi near the centrosomes. (PMID:17352745)
• genetic perturbations in AKAP9 disrupt its binding to KCNQ1 and have a role in long-QT syndrome (PMID:18093912)
• Polymorphisms in AKAP9 M4631 were associated with increased risks for familial and nonfamilial breast cancer. The functional consequence of the AKAP9 M4631 polymorphism may involve the PKA pathway. (PMID:18334708)
• These results provide the first evidence for the microtubule dependent association of AKAP350A and CCAR1 with RNA stress granules. (PMID:19073175)
• Data suggest that recruitment of AKAP450 on Golgi membranes through GM130 allows centrosome-associated nucleating activity to extend to the Golgi, to control the assembly of subsets of microtubules. (PMID:19242490)
• Suppression of AKAP450 by overexpression of a dominant-negative form or siRNA knockdown disrupted the positioning and conformational activation of lymphocyte function-associated antigen 1 at the immune synapse. (PMID:20231423)
• We describe a pathway that integrates Epac-mediated signals with AKAP9-dependent microtubule dynamics to coordinate integrins at lateral borders (PMID:20952690)
• AKAP350 participates in mechanisms which determine the development of canalicular structures as well as accurate canalicular expression of distinct proteins and actin organization (PMID:21374596)
• identification of AKAP450 as a key determinant of pericentrosomal Golgi ribbon integrity, positioning, and function in mammalian cells (PMID:21606206)
• Genotyped 14,843 invasive breast cancer case patients and 19,852 control subjects with white European ancestry and 2595 invasive case patients and 2192 control subjects with Asian ancestry for single nucleotide polymorphism 7q21-rs6964587 (AKAP9-M463I). (PMID:21931171)
• in heart, Yotiao brings together PKA, PP1, PDE4D3, AC9, and the I(Ks) channel to achieve localized temporal regulation of beta-adrenergic stimulation. (PMID:22778270)
• Protein kinase A-phosphodiesterase (PDE)4D3-A kinase anchor protein (AKAP)9 complex generates spatial compartmentalization of cyclic adenosine monophosphate (cAMP) signaling at the centrosome. (PMID:22908311)
• AKAP proteins, most likely AKAP9, maintain the bronchial epithelial barrier by regulating the E-cadherin expression at the cell membrane. (PMID:24452374)
• A590T mutation in KCNQ1 C-terminal helix D decreases KCNE1 channel trafficking and function but not Yotiao interaction. (PMID:24713462)
• AKAP9 has been identified as a Long QT Syndrome Type 1 modifying gene (PMID:25087618)
• This study demonstrated that two rare AKAP9 variants( rs144662445 and rs149979685) are associated with Alzheimer’s disease in African Americans. (PMID:25172201)
• data indicate that MALAT1 may promote CRC tumor development via its target protein AKAP-9 (PMID:25446987)
• Study suggests a role of rare missense variants at NRXN1 and AKAP9 in schizophrenia susceptibility, probably related to alteration of the excitatory/inhibitory synaptic balance, deserving further investigation (PMID:25943950)
• results support a model in which AKAP350 recruits CIP4 to the centrosome, providing a centrosomal scaffold to integrate microtubule and actin dynamics, thus enabling centrosome polarization and ensuring cell migration directionality. (PMID:26208639)
• AKAP9 gene harbors not only somatic frameshift mutations but also mutational ITH. (PMID:26786868)
• Findings suggest MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in CRC cells. These results reveal a novel molecular mechanism by which MALAT1 regulates AKAP-9 expression in CRC cells. (PMID:26887056)
• In cultured colorectal cancer (CRC) cells, knockdown of AKAP-9 inhibited cell proliferation, invasion, and migration. AKAP-9 deficiency also attenuated CRC tumor growth and metastasis in vivo. Mechanistically, AKAP-9 interacted with cdc42 interacting protein 4 (CIP4) and regulated its expression. (PMID:27039663)
• Data suggest that CDK5RAP2 and CEP170 both interact with microtubule nucleation-promoting region of AKAP350A; CEP68 interacts with distal C-terminal region of AKAP350A; AKAP350A spans the bridge between centrioles. (CDK5RAP2 = CDK5 regulatory subunit associated protein 2; CEP170 = centrosomal protein 170kDa; AKAP350A = A kinase (PRKA) anchor protein (yotiao) 9; CEP68 = centrosomal protein 68kDa) (PMID:29054927)
• Data suggest that AKAP350A utilizes organelle-specific targeting domains to promote spatially distinct microtubule nucleation pathways. [REVIEW] (PMID:29247130)
• RNA sequencing identified in both an AKAP9-BRAF gene fusion (PMID:29464327)
• This study shows the impact of rare functional AKAP9 mutations on Tau, a central mechanism of Alzheimer disease pathogenesis (PMID:29516269)
• this study provide critical insights into the roles of CG-NAP in regulating cytoskeletal architecture and T-cell migration (PMID:29545805)
• A-Kinase Anchoring Proteins Diminish TGF-beta1/Cigarette Smoke-Induced Epithelial-To-Mesenchymal Transition. (PMID:32028718)
• Alzheimer’s disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells. (PMID:35567427)
• Expression of RASSF1A, DIRAS3, and AKAP9 Genes in Thyroid Lesions: Implications for Differential Diagnosis and Prognosis of Thyroid Carcinomas. (PMID:38203733)
• A mutation in the cardiac KV7.1 channel possibly disrupts interaction with Yotiao protein. (PMID:38657442)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Akap9	ENSMUSG00000040407
rattus_norvegicus	Akap9	ENSRNOG00000026319

Paralogs (1): PCNT (ENSG00000160299)

Protein

Protein identifiers

A-kinase anchor protein 9 — Q99996 (reviewed: Q99996)

Alternative names: A-kinase anchor protein 350 kDa, A-kinase anchor protein 450 kDa, AKAP 120-like protein, Centrosome- and Golgi-localized PKN-associated protein, Protein hyperion, Protein kinase A-anchoring protein 9, Protein yotiao

All UniProt accessions (20): A0A0A0MRF6, A0A2R8Y590, A0A6I8PUD8, A0A7P0T8N5, A0A7P0T8Z8, A0A7P0T928, A0A7P0T939, A0A7P0T9A9, A0A7P0T9E2, A0A7P0TAA2, A0A7P0TAD6, A0A7P0TAJ1, A0A7P0TAX3, A0A7P0TB09, A0A7P0TBH8, A0A7P0TBI4, A0A7P0Z4N5, A0A7P0Z4Q5, Q99996, H7BYL6

UniProt curated annotations — full annotation on UniProt →

Function. Scaffolding protein that assembles several protein kinases and phosphatases on the centrosome and Golgi apparatus. Required to maintain the integrity of the Golgi apparatus. Required for microtubule nucleation at the cis-side of the Golgi apparatus. Required for association of the centrosomes with the poles of the bipolar mitotic spindle during metaphase. In complex with PDE4DIP isoform 13/MMG8/SMYLE, recruits CAMSAP2 to the Golgi apparatus and tethers non-centrosomal minus-end microtubules to the Golgi, an important step for polarized cell movement. In complex with PDE4DIP isoform 13/MMG8/SMYLE, EB1/MAPRE1 and CDK5RAP2, contributes to microtubules nucleation and extension also from the centrosome to the cell periphery. Associated with the N-methyl-D-aspartate receptor and is specifically found in the neuromuscular junction (NMJ) as well as in neuronal synapses, suggesting a role in the organization of postsynaptic specializations.

Subunit / interactions. Interacts with the regulatory region of protein kinase N (PKN), protein phosphatase 2A (PP2A), protein phosphatase 1 (PP1) and the immature non-phosphorylated form of PKC epsilon. Interacts with CIP4 and FNBP1. Interacts with chloride intracellular channel proteins CLIC1, CLIC4 and CLIC5. CSNK1D binding promotes its centrosomal subcellular location. Interacts with GM130/GOLGA2; leading to recruitment to the Golgi apparatus. Interacts with KCNQ1; targets protein kinase A (PKA) catalytic and regulatory subunits and protein phosphatase 1 (PP1), to the heterodimer KCNQ1-KCNE1. Interacts with PDE4DIP isoform 13/MMG8/SMYLE; this interaction stabilizes both proteins. In complex with PDE4DIP isoform 13, recruits CAMSAP2 to the Golgi apparatus. Forms a pericentrosomal complex with CDK5RAP2, EB1/MAPRE1 and PDE4DIP isoform 13; within this complex, MAPRE1 binding to CDK5RAP2 may be mediated by PDE4DIP. Interacts with MAPRE1 and MAPRE3. Interacts (via C-terminus) with CAMSAP2; this interaction is much stronger in the presence of PDE4DIP isoform 13/MMG8/SMYLE. Interacts with CAMSAP3. Interacts (via C-terminus) with the gamma-tubulin ring complex (gamma-TuRC), composed of gamma-tubulin, TUBGCP2, TUBGCP3, TUBGCP4, TUBGCP5 and TUBGCP6.

Subcellular location. Golgi apparatus. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome.

Tissue specificity. Widely expressed. Isoform 4: Highly expressed in skeletal muscle and in pancreas.

Disease relevance. Long QT syndrome 11 (LQT11) [MIM:611820] A heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. RII-binding site, predicted to form an amphipathic helix, could participate in protein-protein interactions with a complementary surface on the R-subunit dimer.

Isoforms (6)

UniProt ID	Names	Canonical?
Q99996-2	2	yes
Q99996-1	1
Q99996-3	3, CG-NAP
Q99996-4	4, Yotiao
Q99996-5	5
Q99996-6	6, AKAP350

RefSeq proteins (3): NP_001366206, NP_005742, NP_671714 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005539	ELK_dom	Domain
IPR019528	PACT_domain	Domain
IPR028745	AKAP9/Pericentrin	Family

Pfam: PF10495

UniProt features (77 total): sequence conflict 30, coiled-coil region 13, sequence variant 10, modified residue 7, splice variant 7, compositionally biased region 5, region of interest 4, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for Q99996 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 153, 1327, 1765, 3690, 3842, 3865, 3897

Function

Pathways and Gene Ontology

Reactome pathways

24 pathways

ID	Pathway
R-HSA-2565942	Regulation of PLK1 Activity at G2/M Transition
R-HSA-380259	Loss of Nlp from mitotic centrosomes
R-HSA-380270	Recruitment of mitotic centrosome proteins and complexes
R-HSA-380284	Loss of proteins required for interphase microtubule organization from the centrosome
R-HSA-380320	Recruitment of NuMA to mitotic centrosomes
R-HSA-5576890	Phase 3 - rapid repolarisation
R-HSA-5576893	Phase 2 - plateau phase
R-HSA-5620912	Anchoring of the basal body to the plasma membrane
R-HSA-6802952	Signaling by BRAF and RAF1 fusions
R-HSA-8854518	AURKA Activation by TPX2
R-HSA-1640170	Cell Cycle
R-HSA-1643685	Disease
R-HSA-1852241	Organelle biogenesis and maintenance
R-HSA-380287	Centrosome maturation
R-HSA-397014	Muscle contraction
R-HSA-453274	Mitotic G2-G2/M phases
R-HSA-5576891	Cardiac conduction
R-HSA-5617833	Cilium Assembly
R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers
R-HSA-6802957	Oncogenic MAPK signaling
R-HSA-68877	Mitotic Prometaphase
R-HSA-68886	M Phase
R-HSA-69275	G2/M Transition
R-HSA-69278	Cell Cycle, Mitotic

MSigDB gene sets: 418 (showing top): GGGACCA_MIR133A_MIR133B, GOBP_REGULATION_OF_GOLGI_ORGANIZATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_RESPONSE_TO_ELECTRICAL_STIMULUS, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_MICROTUBULE_NUCLEATION, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, CAGCTG_AP4_Q5, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_CELL_CELL_SIGNALING, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS

GO Biological Process (13): microtubule nucleation (GO:0007020), signal transduction (GO:0007165), chemical synaptic transmission (GO:0007268), positive regulation of microtubule polymerization (GO:0031116), protein-containing complex localization (GO:0031503), response to electrical stimulus (GO:0051602), maintenance of centrosome location (GO:0051661), regulation of membrane repolarization (GO:0060306), regulation of ventricular cardiac muscle cell membrane repolarization (GO:0060307), cellular response to cAMP (GO:0071320), regulation of heart rate by cardiac conduction (GO:0086091), regulation of cardiac muscle cell action potential involved in regulation of contraction (GO:0098909), regulation of Golgi organization (GO:1903358)

GO Molecular Function (8): DNA binding (GO:0003677), signaling receptor binding (GO:0005102), potassium channel regulator activity (GO:0015459), protein kinase A regulatory subunit binding (GO:0034237), transmembrane transporter binding (GO:0044325), molecular adaptor activity (GO:0060090), potassium channel activator activity (GO:0099104), protein binding (GO:0005515)

GO Cellular Component (15): Golgi apparatus (GO:0005794), Golgi stack (GO:0005795), cis-Golgi network (GO:0005801), centrosome (GO:0005813), cytosol (GO:0005829), cytoskeleton (GO:0005856), voltage-gated potassium channel complex (GO:0008076), potassium channel complex (GO:0034705), neuronal cell body (GO:0043025), dendritic branch (GO:0044307), synaptic membrane (GO:0097060), glutamatergic synapse (GO:0098978), extrinsic component of postsynaptic density membrane (GO:0099147), cytoplasm (GO:0005737), microtubule organizing center (GO:0005815)

Reactome top-level categories

Rollup of top-12 pathways:

Category	Pathways
G2/M Transition	3
Centrosome maturation	2
Cardiac conduction	2
Loss of proteins required for interphase microtubule organization from the centrosome	1
Mitotic Prometaphase	1
Assembly of the 9+0 primary cilium	1
Oncogenic MAPK signaling	1
Cell Cycle, Mitotic	1
Muscle contraction	1
Organelle biogenesis and maintenance	1
Disease	1
Diseases of signal transduction by growth factor receptors and second messengers	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
microtubule polymerization	2
protein binding	2
potassium channel activity	2
binding	2
cytoplasm	2
intracellular membrane-bounded organelle	2
synapse	2
microtubule cytoskeleton organization	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
anterograde trans-synaptic signaling	1
positive regulation of microtubule polymerization or depolymerization	1
regulation of microtubule polymerization	1
positive regulation of protein polymerization	1
positive regulation of supramolecular fiber organization	1
macromolecule localization	1
response to abiotic stimulus	1
centrosome localization	1
maintenance of organelle location	1
regulation of membrane potential	1
regulation of biological process	1
membrane repolarization	1
regulation of cardiac muscle cell membrane repolarization	1
ventricular cardiac muscle cell membrane repolarization	1
response to cAMP	1
cellular response to nitrogen compound	1
cellular response to oxygen-containing compound	1
regulation of heart rate	1
cardiac conduction	1
cardiac muscle cell action potential	1
regulation of cardiac muscle cell contraction	1
regulation of cardiac muscle cell action potential	1
Golgi organization	1
regulation of organelle organization	1
nucleic acid binding	1
ion channel regulator activity	1

Protein interactions and networks

STRING

3061 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AKAP9	KCNQ1	P51787	993
AKAP9	KCNE1	P15382	969
AKAP9	PRKACA	P17612	968
AKAP9	PRKACG	P22612	967
AKAP9	PRKACB	P22694	967
AKAP9	GOLGA2	Q08379	947
AKAP9	PDE4DIP	Q5VU43	928
AKAP9	AKAP1	Q92667	872
AKAP9	KCNE2	Q9Y6J6	870
AKAP9	SCN4B	Q8IWT1	856
AKAP9	KCNE3	Q9Y6H6	827
AKAP9	SNTA1	Q13424	814
AKAP9	PDE4D	Q08499	809
AKAP9	CALM1	P02593	797
AKAP9	KCNH2	Q12809	794

IntAct

163 interactions, top by confidence:

A	B	Type	Score
STK25	STRN	psi-mi:“MI:0914”(association)	0.900
MAPRE1	CLASP2	psi-mi:“MI:0914”(association)	0.850
CSNK1D	PER2	psi-mi:“MI:0914”(association)	0.810
GSK3A	AXIN1	psi-mi:“MI:0914”(association)	0.800
PRKACB	PRKAR1A	psi-mi:“MI:0914”(association)	0.790
PRKACA	VAPB	psi-mi:“MI:0914”(association)	0.730
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
	PRKAR1A	psi-mi:“MI:0914”(association)	0.700
AKAP9	rep	psi-mi:“MI:0915”(physical association)	0.660
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640
BNIP1	NBAS	psi-mi:“MI:0914”(association)	0.640
STK4	STRN	psi-mi:“MI:0914”(association)	0.610
DISC1	AKAP9	psi-mi:“MI:0915”(physical association)	0.570
ORF	EIF3D	psi-mi:“MI:0914”(association)	0.560
GOLGA2	AKAP9	psi-mi:“MI:0403”(colocalization)	0.540
GOLGA2	AKAP9	psi-mi:“MI:0915”(physical association)	0.540
AKAP9	GOLGA2	psi-mi:“MI:0914”(association)	0.540
rep	TBKBP1	psi-mi:“MI:0914”(association)	0.530
PRKACG	UBB	psi-mi:“MI:0914”(association)	0.530
PRKAR2B	AMY1A	psi-mi:“MI:0914”(association)	0.530
DBF4B	CDC7	psi-mi:“MI:0914”(association)	0.530

BioGRID (313): AKAP9 (Two-hybrid), AKAP9 (Two-hybrid), AKAP9 (Two-hybrid), AKAP9 (Two-hybrid), AKAP9 (Two-hybrid), AKAP9 (Two-hybrid), IKZF3 (Two-hybrid), WAC (Two-hybrid), THAP1 (Two-hybrid), PRDM14 (Two-hybrid), USHBP1 (Two-hybrid), C1orf94 (Two-hybrid), SAMD3 (Two-hybrid), AKAP9 (Affinity Capture-MS), AKAP9 (Affinity Capture-MS)

ESM2 similar proteins: D3ZZL9, E9Q1U1, F4I9A2, O75330, O97961, P49454, P61430, P97779, Q00547, Q03410, Q0VBY1, Q13439, Q14789, Q15075, Q15643, Q28628, Q4R7H3, Q53EZ4, Q5M7B7, Q5RI56, Q5T9S5, Q60563, Q61595, Q62209, Q640L5, Q6TFL3, Q70FJ1, Q7FAD5, Q861Q8, Q86UP2, Q8BL66, Q8CDI7, Q8CHG3, Q8HYY4, Q8IWJ2, Q8NB25, Q8NCX0, Q8R5M4, Q90631, Q90Z16

Diamond homologs: O95613, P48725, Q28628, Q70FJ1, Q99996

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
AKAP9	“up-regulates activity”	TRIP10	binding
ITGAL	“up-regulates activity”	AKAP9	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 180 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
PKA activation	6	29.7×	2e-06
PKA-mediated phosphorylation of CREB	6	26.8×	4e-06
PKA activation in glucagon signalling	5	26.2×	3e-05
DARPP-32 events	6	22.3×	1e-05
Centrosome maturation	10	19.8×	5e-09
Anti-inflammatory response favouring Leishmania parasite infection	6	18.5×	2e-05
Leishmania parasite growth and survival	6	18.5×	2e-05
Calmodulin induced events	6	17.8×	3e-05

GO biological processes:

GO term	Partners	Fold	FDR
vascular endothelial cell response to laminar fluid shear stress	5	23.2×	2e-03
microtubule nucleation	5	19.8×	3e-03
renal water homeostasis	5	16.2×	5e-03
non-motile cilium assembly	6	11.0×	5e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 10 cancer types — BCC, BLCA, BRCA, CCRCC, ESCA, HCC, HNSC, SKCM, STOMACH, UCEC.

Clinical variants and AI predictions

ClinVar

3716 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	4
Uncertain significance	2025
Likely benign	1143
Benign	109

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
3391896	GRCh37/hg19 7q21.2(chr7:91737874-92247201)x1	Pathogenic
180261	NM_005751.5(AKAP9):c.1489G>T (p.Glu497Ter)	Likely pathogenic
207945	NM_005751.5(AKAP9):c.2295T>A (p.Asp765Glu)	Likely pathogenic
207946	NM_005751.5(AKAP9):c.5341T>A (p.Ser1781Thr)	Likely pathogenic
4687971	NM_005751.5(AKAP9):c.571C>T (p.Gln191Ter)	Likely pathogenic

SpliceAI

7260 predictions. Top by Δscore:

Variant	Effect	Δscore
7:91941147:GGTA:G	donor_loss	1.0000
7:91960899:G:T	donor_gain	1.0000
7:91973709:A:AG	acceptor_gain	1.0000
7:91973709:AGCTT:A	acceptor_gain	1.0000
7:91973710:G:GA	acceptor_gain	1.0000
7:91973710:GC:G	acceptor_gain	1.0000
7:91973710:GCT:G	acceptor_gain	1.0000
7:91973710:GCTT:G	acceptor_gain	1.0000
7:91973710:GCTTG:G	acceptor_gain	1.0000
7:91973965:GGAA:G	donor_gain	1.0000
7:91973966:GAA:G	donor_gain	1.0000
7:91973966:GAAG:G	donor_gain	1.0000
7:91973967:AAG:A	donor_loss	1.0000
7:91973968:AGTA:A	donor_loss	1.0000
7:91973969:G:GG	donor_gain	1.0000
7:91973970:TAAG:T	donor_loss	1.0000
7:91980277:T:G	acceptor_gain	1.0000
7:91980281:T:TA	acceptor_gain	1.0000
7:91980285:TTA:T	acceptor_loss	1.0000
7:91980286:TAG:T	acceptor_loss	1.0000
7:91980287:A:AG	acceptor_gain	1.0000
7:91980287:AGC:A	acceptor_loss	1.0000
7:91980287:AGCT:A	acceptor_gain	1.0000
7:91980288:G:A	acceptor_loss	1.0000
7:91980288:G:GG	acceptor_gain	1.0000
7:91980288:GC:G	acceptor_gain	1.0000
7:91980288:GCT:G	acceptor_gain	1.0000
7:91980288:GCTG:G	acceptor_gain	1.0000
7:91980331:GAG:G	donor_gain	1.0000
7:91980332:AGGTA:A	donor_loss	1.0000

AlphaMissense

26002 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:91994673:T:C	L210P	0.999
7:92001716:T:C	L600P	0.999
7:92102631:G:C	R3712P	0.999
7:92102640:T:C	L3715P	0.999
7:92102661:T:C	L3722P	0.999
7:92001742:G:C	A609P	0.998
7:92001760:G:C	A615P	0.998
7:92001775:G:C	A620P	0.998
7:92102681:T:C	F3729L	0.998
7:92102683:C:A	F3729L	0.998
7:92102683:C:G	F3729L	0.998
7:91973720:T:C	F20L	0.997
7:91973722:T:A	F20L	0.997
7:91973722:T:G	F20L	0.997
7:92001710:T:C	I598T	0.997
7:92001714:A:C	K599N	0.997
7:92001714:A:T	K599N	0.997
7:92001766:T:C	S617P	0.997
7:92001791:T:C	L625P	0.997
7:92001803:T:C	L629P	0.997
7:92040762:T:C	L1594P	0.997
7:92052927:T:C	L1857P	0.997
7:92065287:G:C	A2012P	0.997
7:92066463:T:C	F2083L	0.997
7:92066465:C:A	F2083L	0.997
7:92066465:C:G	F2083L	0.997
7:92070082:T:C	L2128P	0.997
7:92076898:T:C	L2219P	0.997
7:92108595:T:C	L3883P	0.997
7:91941117:A:C	R6S	0.996

dbSNP variants (sampled 300 via entrez): RS1000029387 (7:92026803 A>T), RS1000036589 (7:92074097 G>T), RS1000051875 (7:92018770 C>A,T), RS1000071691 (7:92089766 C>G), RS1000083763 (7:92020487 C>T), RS1000089599 (7:91944163 G>C), RS1000127763 (7:91981766 C>T), RS1000138441 (7:91974419 A>G), RS1000206209 (7:92072538 A>G), RS1000215053 (7:91967654 T>C), RS1000220474 (7:91996294 C>T), RS1000246429 (7:91986803 A>G), RS1000267583 (7:92013844 T>C,G), RS1000268950 (7:92032845 A>C,G), RS1000278018 (7:92080514 T>C)

Disease associations

OMIM: gene MIM:604001 | disease phenotypes: MIM:611820, MIM:114500, MIM:613688, MIM:192500, MIM:601144, MIM:604772, MIM:194200

GenCC curated gene-disease

Disease	Classification	Inheritance
male infertility with azoospermia or oligozoospermia due to single gene mutation	Moderate	Autosomal recessive
long QT syndrome 11	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
long QT syndrome	Disputed	AD

Mondo (24): long QT syndrome (MONDO:0002442), long QT syndrome 11 (MONDO:0012738), cardiomyopathy (MONDO:0004994), colorectal cancer (MONDO:0005575), dilated cardiomyopathy (MONDO:0005021), ventricular tachycardia (MONDO:0005477), cardiac arrest (MONDO:0000745), long QT syndrome 2 (MONDO:0013367), ventricular fibrillation (MONDO:0000190), long QT syndrome 1 (MONDO:0100316), cardiac rhythm disease (MONDO:0007263), Brugada syndrome 1 (MONDO:0011001), catecholaminergic polymorphic ventricular tachycardia (MONDO:0017990), hypertrophic cardiomyopathy (MONDO:0005045), arrhythmogenic right ventricular cardiomyopathy (MONDO:0016587)

Orphanet (12): Romano-Ward syndrome (Orphanet:101016), Congenital long QT syndrome (Orphanet:768), Rare cardiomyopathy (Orphanet:167848), Dilated cardiomyopathy (Orphanet:217604), Brugada syndrome (Orphanet:130), Catecholaminergic polymorphic ventricular tachycardia (Orphanet:3286), Rare hypertrophic cardiomyopathy (Orphanet:217569), Inherited arrhythmogenic cardiomyopathy (Orphanet:247), Amyloidosis (Orphanet:69), Restrictive cardiomyopathy (Orphanet:217632), NON RARE IN EUROPE: Colorectal cancer (Orphanet:466667), NON RARE IN EUROPE: Wolff-Parkinson-White syndrome (Orphanet:907)

HPO phenotypes

25 total (30 of 25 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000365	Hearing impairment
HP:0001197	Abnormality of prenatal development or birth
HP:0001250	Seizure
HP:0001279	Syncope
HP:0001645	Sudden cardiac death
HP:0001649	Tachycardia
HP:0001663	Ventricular fibrillation
HP:0001664	Torsade de pointes
HP:0001688	Sinus bradycardia
HP:0001695	Cardiac arrest
HP:0002900	Hypokalemia
HP:0003621	Juvenile onset
HP:0004308	Ventricular arrhythmia
HP:0004751	Paroxysmal ventricular tachycardia
HP:0004755	Supraventricular tachycardia
HP:0005135	Abnormal T-wave
HP:0005184	Prolonged QTc interval
HP:0011704	Sick sinus syndrome
HP:0011705	First degree atrioventricular block
HP:0011712	Complete right bundle branch block
HP:0011715	Trifascicular block
HP:0012251	ST segment elevation
HP:0012332	Abnormal autonomic nervous system physiology
HP:0500018	Abnormal cardiac exercise stress test
HP:0001644	Dilated cardiomyopathy
HP:0001639	Hypertrophic cardiomyopathy
HP:0011034	Amyloid deposition
HP:0005110	Atrial fibrillation
HP:0001716	Wolff-Parkinson-White syndrome

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002263_9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	3.000000e-06
GCST004988_209	Breast cancer	9.000000e-11
GCST006396_9	Disrupted circadian rhythm (low relative amplitude of rest-activity cycles)	2.000000e-06
GCST006993_10	Hippocampal volume in Alzheimer’s disease dementia	2.000000e-07
GCST006997_2	Cerebrospinal fluid t-tau levels in mild cognitive impairment	5.000000e-06
GCST006998_4	Cerebrospinal fluid p-tau levels in mild cognitive impairment	3.000000e-07
GCST90000025_353	Appendicular lean mass	1.000000e-13
GCST90002403_578	Red blood cell count	3.000000e-12

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005533	response to non-steroidal anti-inflammatory
EFO:0005035	hippocampal volume
EFO:0004760	t-tau measurement
EFO:0004980	appendicular lean mass
EFO:0004305	erythrocyte count

MeSH disease descriptors (17)

Descriptor	Name	Tree numbers
D000686	Amyloidosis	C18.452.845.500
D019571	Arrhythmogenic Right Ventricular Dysplasia	C14.240.400.145; C14.280.238.028; C14.280.400.145; C16.131.240.400.145
D001281	Atrial Fibrillation	C14.280.067.198; C23.550.073.198
D053840	Brugada Syndrome	C14.280.067.322; C14.280.123.250; C16.320.100
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D009202	Cardiomyopathies	C14.280.238
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160
D002313	Cardiomyopathy, Restrictive	C14.280.238.160
D006323	Heart Arrest	C14.280.383
D006333	Heart Failure	C14.280.434
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547
D017180	Tachycardia, Ventricular	C14.280.067.845.940; C14.280.123.875.940; C23.550.073.845.940
D014693	Ventricular Fibrillation	C14.280.067.922; C23.550.073.922
D014927	Wolff-Parkinson-White Syndrome	C14.280.067.780.977; C14.280.123.750.977; C16.131.240.400.980
C567513	Long Qt Syndrome 11 (supp.)
C563614	Long Qt Syndrome 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

60 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, decreases methylation	9
sodium arsenite	affects localization, decreases reaction, affects methylation, decreases expression	4
trichostatin A	affects cotreatment, decreases expression	3
Tretinoin	affects cotreatment, decreases expression, increases expression	3
Arsenic Trioxide	affects expression, increases expression, affects cotreatment, decreases expression	2
Formaldehyde	decreases expression, increases expression	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, decreases methylation	1
dicrotophos	decreases expression	1
4-methyl-7-diethylaminocoumarin	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
cobaltous chloride	increases expression	1
butyraldehyde	decreases expression	1
zinc chromate	increases abundance, increases expression	1
1,10-phenanthroline	increases expression	1
epigallocatechin gallate	decreases expression	1
tamibarotene	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases abundance, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases response to substance, increases expression	1
eprenetapopt	decreases expression, affects reaction	1
jinfukang	decreases expression	1

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C6U7	ZZUSAHi004-A	Induced pluripotent stem cell	Male
CVCL_SC07	HAP1 AKAP9 (-) 1	Cancer cell line	Male
CVCL_SC08	HAP1 AKAP9 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

299 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT00348530	PHASE4	UNKNOWN	Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
NCT00371891	PHASE4	COMPLETED	Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
NCT00401856	PHASE4	COMPLETED	CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
NCT00559338	PHASE4	COMPLETED	Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department
NCT00606775	PHASE4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00658203	PHASE4	COMPLETED	Clinical Evaluation on Advanced Resynchronization
NCT00701220	PHASE4	COMPLETED	Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
NCT00800761	PHASE4	COMPLETED	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT00806390	PHASE4	TERMINATED	Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
NCT01006473	PHASE4	COMPLETED	Exercise Training in Chagas Cardiomyopathy
NCT01261065	PHASE4	COMPLETED	Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
NCT01345188	PHASE4	COMPLETED	Ranolazine in Ischemic Cardiomyopathy
NCT01868841	PHASE4	COMPLETED	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
NCT02640846	PHASE4	UNKNOWN	Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
NCT03228823	PHASE4	UNKNOWN	Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)
NCT04323852	PHASE4	COMPLETED	Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
NCT05034432	PHASE4	RECRUITING	The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
NCT05718128	PHASE4	RECRUITING	Clinical Study of Endocardial Myocardial Biopsy
NCT06964464	PHASE4	RECRUITING	Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT00170183	PHASE3	COMPLETED	Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure
NCT00270387	PHASE3	COMPLETED	A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
NCT00321295	PHASE3	COMPLETED	Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
NCT00483197	PHASE3	UNKNOWN	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
NCT00490321	PHASE3	UNKNOWN	VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
NCT00626028	PHASE3	COMPLETED	Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
NCT01013714	PHASE3	UNKNOWN	Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
NCT01217827	PHASE3	COMPLETED	Implantable Cardioverter-Defibrillator Use in the VA System
NCT01648634	PHASE3	COMPLETED	Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
NCT02924285	PHASE3	COMPLETED	Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease
NCT03860935	PHASE3	COMPLETED	Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT04166331	PHASE3	COMPLETED	Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
NCT05175066	PHASE3	COMPLETED	Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT06158698	PHASE3	RECRUITING	CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
NCT06563895	PHASE3	RECRUITING	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06846086	PHASE3	RECRUITING	Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy